Amino alcohol derivative and immunosuppresive agent having same as an active ingredient
| Title: | Amino alcohol derivative and immunosuppresive agent having same as an active ingredient |
|---|---|
| Patent Number: | 8,273,748 |
| Publication Date: | September 25, 2012 |
| Appl. No: | 12/310018 |
| Application Filed: | August 07, 2007 |
| Abstract: | An amino alcohol derivative useful as an excellent immunosuppressive agent is provided. As a result of intensive research to create a highly safe compound which has an excellent immunosuppressive activity, it was discovered that an amino alcohol derivative represented by the general formula (1), [chemical expression included] has excellent immunosuppressive activity. |
| Inventors: | Kohno, Yasushi (Tochigi, JP); Fujii, Kiyoshi (Tochigi, JP); Saito, Tatsuhiro (Tochigi, JP); Kuriyama, Kazuhiko (Tochigi, JP); Yasue, Tokutarou (Tochigi, JP) |
| Assignees: | Kyorin Pharmaceutical Co., Ltd. (Tokyo, JP) |
| Claim: | 1. An amino alcohol derivative represented by the general formula (1a), [chemical expression included] wherein R 3 represents a methyl group, X represents an oxygen atom or a sulfur atom, and n denotes 2 or 3, or a pharmaceutically acceptable salt thereof. |
| Claim: | 2. A pharmaceutical comprising the amino alcohol derivative, or a pharmaceutically acceptable salt thereof, according to claim 1 as an active ingredient. |
| Claim: | 3. The pharmaceutical according to claim 2 , being an immunosuppressive agent. |
| Claim: | 4. The pharmaceutical according to claim 2 , being a rejection treatment agent in organ transplants or bone marrow transplants. |
| Claim: | 5. A pharmaceutical comprising the amino alcohol derivative, or a pharmaceutically acceptable salt thereof, according to claim 1 and a calcineurin inhibitor in combination. |
| Claim: | 6. The amino alcohol derivative according to claim 1 , wherein the compound represented by the general formula (1a) is, (R)-2-amino-5-[2-chloro-4-(3-trifluoromethylphenylthio)phenyl]-2-methylpentan- 1 -ol, or a pharmaceutically acceptable salt thereof. |
| Claim: | 7. A pharmaceutical comprising the amino alcohol derivative, or a pharmaceutically acceptable salt thereof, according to claim 6 as an active ingredient. |
| Claim: | 8. A pharmaceutical comprising the amino alcohol derivative, or a pharmaceutically acceptable salt thereof, according to claim 6 and a calcineurin inhibitor in combination. |
| Claim: | 9. The amino alcohol derivative according to claim 1 , wherein the compound represented by the general formula (1a) is a compound represented by the formula (1b), [chemical expression included] or a pharmaceutically acceptable salt thereof. |
| Claim: | 10. A pharmaceutical comprising the amino alcohol derivative, or a pharmaceutically acceptable salt thereof, according to claim 9 as an active ingredient. |
| Claim: | 11. An amino alcohol derivative represented by the general formula (1), [chemical expression included] wherein R 1 represents a trifluoromethyl group, R 2 represents a chlorine atom, R 3 represents a methyl group, X represents an oxygen atom or a sulfur atom, and n denotes 2 or 3, or a pharmaceutically acceptable salt thereof, being obtainable by a step of allowing a compound represented by the general formula (2), [chemical expression included] wherein R 1 represents a trifluoromethyl group, R 2 represents a chlorine atom, A represents a halogen atom, X represents an oxygen atom or a sulfur atom, and n denotes 2 or 3, and a compound represented by the general formula (10), [chemical expression included] wherein R 3 represents a methyl group and R 4 represents an alkyl group having 1 to 6 carbon atoms to react in the presence of a base, and a step of subjecting the resultant product to acidolysis, then further protecting a nitrogen atom with a t-butoxycarbonyl group, reducing, and deprotecting the nitrogen atom. |
| Claim: | 12. A pharmaceutical comprising the amino alcohol derivative, or a pharmaceutically acceptable salt thereof, according to claim 11 as an active ingredient. |
| Claim: | 13. A pharmaceutical comprising the amino alcohol derivative, or a pharmaceutically acceptable salt thereof, according to claim 11 and a calcineurin inhibitor in combination. |
| Claim: | 14. (−)-2-Amino-5-[2-chloro-4-(3-trifluoromethylphenylthio)phenyl]-2-methylpentan-1-ol, or a pharmaceutically acceptable salt thereof. |
| Claim: | 15. A method for treating a rejection in organ transplantation or bone marrow transplantation in a patient, comprising administering to a patient in need thereof a therapeutically effective amount of an amino alcohol derivative represented by the general formula (1a), [chemical expression included] wherein R 3 represents a methyl group, X represents an oxygen atom or a sulfur atom, and n denotes 2 or 3, or a pharmaceutically acceptable salt thereof, as an active ingredient. |
| Claim: | 16. The method according to claim 15 , wherein the compound is (R)-2-amino-5- [2-chloro-4-(3-trifluoromethylphenylthio)phenyl]-2- methylpentan-1-ol, or a pharmaceutically acceptable salt thereof. |
| Current U.S. Class: | 5142/521 |
| Patent References Cited: | 5447922 September 1995 Lawrence et al. 5604229 February 1997 Fujita et al. 5948820 September 1999 Fujita et al. 6004565 December 1999 Chiba et al. 6214873 April 2001 Adachi et al. 6489331 December 2002 Shimada et al. 6960692 November 2005 Kohno et al. 6963012 November 2005 Kohno et al. 7456157 November 2008 Kohno et al. 7482491 January 2009 Kohno et al. 2002/0040050 April 2002 Xu et al. 2002/0091105 July 2002 Mandala et al. 2002/0143034 October 2002 Taniguchi et al. 2003/0236297 December 2003 Nishi et al. 2004/0058894 March 2004 Doherty et al. 2004/0067908 April 2004 Nakade et al. 2004/0087662 May 2004 Bigaud et al. 2004/0110728 June 2004 Macdonald et al. 2004/0138462 July 2004 Sakurai et al. 2004/0147490 July 2004 Albert et al. 2004/0224941 November 2004 Seko et al. 2004/0235794 November 2004 Nakade et al. 2004/0242654 December 2004 Kohno et al. 2004/0248952 December 2004 Pan et al. 2004/0254222 December 2004 Kohno et al. 2005/0009786 January 2005 Pan et al. 2005/0020837 January 2005 Doherty et al. 2005/0033055 February 2005 Bugianesi et al. 2005/0043386 February 2005 Nishi et al. 2005/0107345 May 2005 Doherty et al. 2005/0222422 October 2005 Lynch et al. 2005/0245575 November 2005 Chen et al. 2006/0046979 March 2006 Foster et al. 2006/0089334 April 2006 Budhu et al. 2006/0135622 June 2006 Kohno et al. 2006/0135786 June 2006 Saha et al. 2006/0148830 July 2006 Terakado et al. 2006/0148844 July 2006 Nakade et al. 2006/0160771 July 2006 Kohno et al. 2006/0161005 July 2006 Doherty et al. 2006/0166940 July 2006 Buehlmayer et al. 2006/0211656 September 2006 Albert et al. 2006/0211658 September 2006 Hinterding et al. 2006/0252741 November 2006 Colandrea et al. 2006/0264403 November 2006 Albert 2007/0010494 January 2007 Ehrhardt et al. 2007/0043014 February 2007 Doherty et al. 2007/0088002 April 2007 Lynch et al. 2007/0135501 June 2007 Hinterding et al. 2007/0149597 June 2007 Nishi et al. 2007/0167410 July 2007 Pan et al. 2007/0167425 July 2007 Nakade et al. 2007/0191468 August 2007 Nishi et al. 2007/0203100 August 2007 Pan et al. 2007/0225260 September 2007 Hinterding et al. 2008/0025973 January 2008 Fleenor et al. 2008/0027508 January 2008 Chu 2008/0032923 February 2008 Kudou et al. 2008/0153882 June 2008 Nishi et al. 2008/0161410 July 2008 Kusters et al. 2008/0200438 August 2008 Albert et al. 2008/0207584 August 2008 Habashita et al. 2008/0207941 August 2008 Tsubuki et al. 2008/0249093 October 2008 Colandrea et al. 2009/0023797 January 2009 Azzaoui et al. 2002-53575 February 2002 2002-316985 October 2002 2003-137894 May 2003 2003-267936 September 2003 2004-137208 May 2004 2004-307439 November 2004 2004-307440 November 2004 2004-307441 November 2004 2004-307442 November 2004 2005-47899 February 2005 2005-247691 September 2005 01/98301 December 2001 WO 03/029184 April 2003 03/040097 May 2003 03/051876 June 2003 2004/026817 April 2004 WO 2004/026817 April 2004 2005/014525 February 2005 2005/014603 February 2005 2005/063671 July 2005 2006/041015 April 2006 2006/063033 June 2006 2006/129688 December 2006 2007/043433 April 2007 2007/043568 April 2007 2007/091501 August 2007 2007/126042 November 2007 |
| Other References: | STN Search Report (Accession No. 2003:282516). cited by examiner Han (Advances in Characterization of Pharmaceutical Hydrates. Trends in Bio/Pharmaceutical Industry, pp. 25-29. Mar. 2006). cited by examiner Vippagunta et al (Adv Drug Deliv Rev 48:3-26, 2001). cited by examiner International Search Report dated Oct. 2, 2007 in the International (PCT) Application PCT/JP2007/065426 of which the present application is the U.S. National Stage. cited by other Blam et al., Integrating Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease: Current and Future Perspectives, Am. J. Gastroenterology, 2001, vol. 96, No. 7, pp. 1977-1997. cited by other Keller et al., Immunomodulator FTY720 Induces Myofibroblast Differentiation via the Lysophospholipid Receptor S1P3 and Smad3 Signaling, Am. J. Pathology, Jan. 2007, vol. 170, No. 1, pp. 281-292. cited by other Yasuyuki Igarashi, Sphingosine-1-Phosphate as an Intercellular Signaling Molecule, Ann. NY Acad. Sci., 1998, vol. 845, pp. 19-31. cited by other Jacobs et al., Intramuscular Interferon Beta-1a for Disease Progression in Relapsing Multiple Sclerosis, Ann. Neurol., 1996, vol. 39, No. 3, pp. 285-294. cited by other Weinshenker et al., A Randomized Trial of Plasma Exchange in Acute Central Nervous System Inflammatory Demyelinating Disease, Ann. Neurol., 1999, vol. 46, No. 6, pp. 878-886. cited by other Ganem et al., The Molecular Biology of the Hepatitis B Virus, Annu. Rev. Biochem., 1987, vol. 56 pp. 651-693. cited by other Kaneko et al., Sphingosine-1-phosphate receptor agonists suppress concanavalin A-induced hepatic injury in mice, Biochem. and Biophys. Res. Commun., 2006, vol. 345, pp. 85-92. cited by other Okazaki et al., Molecular Cloning of a Novel Putative G Protein-Coupled Receptor Expressed in the Cardiovascular System, Biochem. and Biophys. Res. Commun., 1993, vol. 190, No. 3, pp. 1104-1106. cited by other Klein et al., Total Synthesis and Antifungal Evaluation of Cyclic Aminohexapeptides, Bioorg. Med. Chem., 2000, vol. 8, pp. 167-1696. cited by other Hashimoto et al., 13-Phenylselenoalanine as a dehydroalanine precursor-efficient synthesis of alternariolide (AM-toxin I), Chem. Commun., 1996, pp. 1139-1140. cited by other Levkau et al., High-Density Lipoprotein Stimulates Myocardial Perfusion in Vivo, Circulation, 2004, vol. 110, pp. 3355-3359. cited by other Salomone et al., S1P3 receptors mediate the potent constriction of cerebral arteries by sphingosine-1-phosphate, Eur. J. Pharmacol., 2003, vol. 469, pp. 125-134. cited by other Heneghan et al., Current and Novel Immunosuppressive Therapy for Autoimmune Hepatitis, Hepatology, 2002, vol. 35, No. 1, pp. 7-13. cited by other Francis V. Chisari, Cytotoxic T Cells and Viral Hepatitis, J. Clin. Invest., Apr. 1997, vol. 99, No. 7, pp. 1472-1477. cited by other Kiuchi et al., Synthesis and Immunosuppressive Activity of 2-Substituted 2-Aminopropane-1,3-diols and 2-Aminoethanols, J. Med. Chem., 2000, vol. 43, pp. 2946-2961. cited by other Brinkmann et al., The Immune Modulator FTY720 Targets Sphingosine 1-Phosphate Receptors, J. Biol. Chem., 2002, vol. 277, No. 24, pp. 21453-21457. cited by other Sanna et al., Sphingosine 1-Phosphate (S1P) Receptor Subtypes S1P1 and S1P3, Respectively, Regulate Lymphocyte Recirculation and Heart Rate, J. Biol. Chem., Apr. 2, 2004, vol. 279, No. 14, pp. 13839-13848. cited by other Forrest et al., Immune Cell Regulation and Cardiovascular Effects of Sphingosine 1-Phosphate Receptor Agonists in Rodents are Mediated via Distinct Receptor Subtypes, J. Pharm. Exp. Ther., 2004, vol. 309, No. 2, pp. 758-768. cited by other George C. Ebers, Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis, Lancet, Nov. 7, 1998, vol. 352, pp. 1498-1501. cited by other Takuwa et al., Subtype-specific, differential activities of the EDG family receptors for sphingosine-1-phosphate, a novel lysophospholipid mediator, Mol. Cell. Endocrinol., 2001, vol. 177, pp. 3-11. cited by other Fried et al., Peginterferon Alfa-2a Plus Ribavirin for Chronic Hepatitis C Virus Infection, N. Engl. J. Med., Sep. 26, 2002, vol. 347, No. 13, pp. 975-982. cited by other Mailliard et al., Suppressing Hepatitis B without Resistance—So Far, So Good, N. Engl. J. Med., Feb. 27, 2003, vol. 348, No. 9, pp. 848-850. cited by other Niessen et al., Dentritic cell PAR1-S1P3 signalling couples coagulation and inflammation, Nature, Apr. 3, 2008, vol. 452, No. 3, pp. 654-658. cited by other INFB Multiple Sclerosis Study Group, Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial, Neurology, Apr. 1993, vol. 43, pp. 655-661. cited by other Paty et al., Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial, Neurology, Apr. 1993, vol. 43, pp. 662-667. cited by other Johnson et al., Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: Results of a phase III multicenter, double-blind, placebo-controlled trial, Neurology, Jul. 1995, vol. 45, pp. 1268-1276. cited by other Zivadinov et al., Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS, Neurology, 2001, vol. 57, pp. 1239-1247. cited by other Goodin et al., Disease modifying therapies in multiple sclerosis; Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines, Neurology, 2002, vol. 58, pp. 169-178. cited by other Rudick et al., Management of Multiple Cclerosis, N. Engl. J. Med., Nov. 27, 1997, vol. 337, No. 22, pp. 1604-1611. cited by other Daniel K. Podolsky, Inflammatory Bowel Disease, N. Engl. J. Med., Aug. 8, 2002, vol. 347, No. 6, pp. 417-429. cited by other Kappos et al., Oral Fingolimod (FTY720) for Relapsing Multiple Sclerosis, N. Engl. J. Med., Sep. 14, 2006, vol. 355, No. 11, pp. 1124-1140. cited by other Viscido et al., Inflammatory bowel diseases: clinical update of practical guidelines, Nucl. Med. Commun., 2005, vol. 26, No. 7, pp. 649-655. cited by other Gon et al., S1P3 receptor-induced reorganization of epithelial tight junctions comprises lung barrier integrity and is potentiated by TNF, PNAS, Jun. 28, 2005, vol. 102, No. 26, pp. 9270-9275. cited by other Saito et al., Hepatitis C virus infection is associated with the development of hepatocellular carcinoma, Proc. Natl. Acad. Sci. USA, Sep. 1990, vol. 87, pp. 6547-6549. cited by other Mandala et al., Alteration of Lymphocyte Trafficking by Sphingosine-1-Phosphate Receptor Agonists, Science, Apr. 2, 2002, vol. 296, pp. 346-349. cited by other Hinterding et al., Synthesis of Chiral Analogues of FTY720 and its Phosphate, Synthesis, 2003, No. 11, pp. 1667-1670. cited by other Campbell et al., The Synthesis of Novel Amino Acids via Hydroboration-Suzuki Cross Coupling, Tetrohedron Letters, 1999, vol. 40, pp. 5263-5266. cited by other Collier et al., The direct synthesis of novel enantiomerically pure α-amino acids in protected form via suzuki cross-coupling, Tetrahedron Letters, 2000, vol. 41, pp. 7115-7119. cited by other Long et al., Enantioselective syntheses of homophenylalanine derivatives via nitron 1,3-dipolar cycloaddition reactions with styrenes, Tetrahedron Letters, 2001, vol. 42, pp. 5343-5345. cited by other Shimizu et al., KRP-203, a Novel Synthetic Immunosuppressant, Prolongs Graft Survival and Attenuates Chronic Rejection in Rat Skin and Heart Allografts, Circulation, 2005, vol. 111, pp. 222-229. cited by other Takahashi et al., a Novel Immunomodulator KRP-203 Combined with Cyclosporine Prolonged Graft Survival and Abrogated Transplant Vasculopathy in Rat Heart Allografts, Transplant. Proc., 2005, vol. 37, pp. 143-145. cited by other Kohno, Yasushi et al., “Discovery of KRP-203, a potent and orally active new type of immunosuppressant, sphingosine-1-phosphate receptor agonist”, From Abstracts of Papers, 229th ACS National Meeting, San Diego, CA, U.S., Mar. 13-17, 2005. cited by other English translation of Office Action issued Oct. 21, 2010 in Russian Application corresponding to U.S. Appl. No. 12/083,224. cited by other Julien Davaille et al., “Sphingosine 1-Phosphate Triggers Both Apoptotic and Survival Signals for Human Hepatic Myofibroblasts”, J. Biol. Chem., vol. 277, No. 40, pp. 37323-37330 (2002). cited by other |
| Primary Examiner: | Ricci, Craig |
| Attorney, Agent or Firm: | Wenderoth, Lind & Ponack, L.L.P. |
| Accession Number: | edspgr.08273748 |
| Database: | USPTO Patent Grants |
| Language: | English |
|---|